Stockscreener 앱 받기
6.07
3.19%
-0.20
시장 영업 전:
6.11
0.04
+0.66%
Novavax Inc 주식(NVAX)의 최신 뉴스
Novavax to Participate in BofA Securities 2025 Health Care Conference | NVAX Stock News - GuruFocus
Novavax to Participate in BofA Securities 2025 Health Care Conference - Stock Titan
Novavax COVID-19 vaccine sparks uncertainty about other shots - Mid Florida Newspapers
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Longview News-Journal
Novavax (NasdaqGS:NVAX) And Takeda Amend Collaboration For SARS-CoV-2 Vaccine In Japan - Yahoo Finance
Japan Enhances Non-mRNA COVID-19 Vaccine Availability - Vax-Before-Travel
Novavax reports revised terms for Takeda agreement for Nuvaxovid in Japan - MSN
Novavax (NVAX) Strengthens Partnership with Takeda for Nuvaxovid in Japan - GuruFocus
Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan - marketscreener.com
B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating - marketscreener.com
Novavax revises Takeda deal for Japan vaccine sales - Investing.com
Novavax revises Takeda deal for Japan vaccine sales By Investing.com - Investing.com India
Novavax Announces Improved Financial Terms In Its Agreement With Takeda For Nuvaxovid In Japan - Nasdaq
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan | NVAX Stock News - GuruFocus
Novavax (NVAX) Updates Agreement with Takeda for Nuvaxovid in Japan | NVAX Stock News - GuruFocus
Novavax Secures Enhanced Takeda Deal for COVID Vaccine in Japan Market | NVAX Stock News - Stock Titan
Novavax to Report First-Quarter Earnings: Is a Beat in Store? - Yahoo Finance
Novavax told by FDA to conduct additional study for COVID vaccinereport - MSN
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Novavax (NVAX) Flat As Market Gains: What You Should Know - Yahoo Finance
Novavax (NVAX) Sees Increased Bearish Options Activity | NVAX Stock News - GuruFocus
RFK Jr.’s New Vaccine Scrutiny Is Alarming - Bloomberg.com
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots - Bluefield Daily Telegraph
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 | NVAX Stock News - GuruFocus
Novavax Q1 2025 Earnings Call Coming Next Week: Key Details for Investors - Stock Titan
FDA to Require Placebo-Controlled Trials for Vaccine Approvals - Bloomberg.com
US FDA Commissioner’s Office Plans Involvement In Many Approvals In Potential Major Change - insights.citeline.com
Novavax expands board, appoints Charles W. Newton as director - Investing.com Australia
Novavax appoints Charles Newton to board of directors - Investing.com
Novavax expands board, appoints Charles W. Newton as director By Investing.com - Investing.com Nigeria
Novavax appoints Charles Newton to board of directors By Investing.com - Investing.com India
FDA Scrutiny of Novavax COVID Shot Sparks Uncertainty About Other Vaccines - MedPage Today
Novavax (NVAX) Welcomes Charles Newton to Board of Directors | N - GuruFocus
Novavax Appoints Charles Newton to Board of Directors | NVAX Sto - GuruFocus
Novavax Appoints Charles Newton To Board Of Directors - marketscreener.com
Novavax Appoints Charles Newton to Board of Directors - Quantisnow
Novavax Appoints Charles Newton to Board of Directors – Company Announcement - Financial Times
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline - Benzinga
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty - TelegraphHerald.com
NVAX Engages with Shah Capital for Strategic Growth Initiatives - GuruFocus
FDA Scrutiny Of Novavax COVID-19 Vaccine Sparks Uncertainty About Other Shots - Barchart.com
Does the Novavax delay augur a COVID vaccine policy change? - pharmaphorum
Nvidia & chip stocks falling, Novavax vaccine, Zscaler upgrade - Yahoo Finance
Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. - Barron's
Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny - Endpoints News
Novavax says vaccine application still ‘approvable,’ despite FDA delay - BioPharma Dive
Novavax Stock Is Up Again on More Covid Shot News and Speculation - Barron's
FDA's Continued Delay on Novavax (NVAX) Vaccine Approval Raises Concerns | NVAX Stock News - GuruFocus
Novavax’s COVID-19 Vaccine Awaits FDA Decision Amid Request For More Data - The Seattle Medium
Lobbying Update: $170,000 of NOVAVAX INC lobbying was just disclosed - Nasdaq
5.24%
자본화:
|
볼륨(24시간):